Ghaziabad Online

Refractory Multiple Myeloma Pipeline Analysis of 80+ therapies: Key Pharma Players Set to Develop Novel Therapies

 Breaking News
  • No posts were found

Refractory Multiple Myeloma Pipeline Analysis of 80+ therapies: Key Pharma Players Set to Develop Novel Therapies

September 27
22:59 2022
Refractory Multiple Myeloma Pipeline Analysis of 80+ therapies: Key Pharma Players Set to Develop Novel Therapies

DelveInsight’s ‘Refractory Multiple Myeloma Pipeline Insight 2022‘ report provides comprehensive global coverage of available, marketed, and pipeline refractory multiple myeloma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the refractory multiple myeloma pipeline domain.

 

The increasing incidence, rise in healthcare investments, and a number of diagnoses among patients are driving the growth of the market. Major players that are developing potential therapies in the late stage of development include Janssen Research & Development, LLC, MorphoSys/ I-Mab Biopharma, Rapa Therapeutics, Arcellx, Inc., Novartis, and several others.

 

Key Takeaways from the Refractory Multiple Myeloma Pipeline Report

  • DelveInsight’s refractory multiple myeloma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for refractory multiple myeloma treatment. 
  • Key refractory multiple myeloma companies such as NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, Amgen, Pfizer, Rapa Therapeutics, Arcellx, Inc., Gilead Sciences, Novartis, Celgene Corporation, Genmab, Harpoon Therapeutics, Cytovia Therapeutics, Ichnos Sciences, Poseida Therapeutics, Allogene Therapeutics, Seagen Inc., Regeneron Pharmaceuticals, CFT7455, C4 Therapeutics, CARsgenTherapeutics Co.,Ltd, CELLECTAR BIOSCIENCES, INC., Nektar Therapeutics, iTeos Therapeutics, CASI Pharmaceuticals, Fate Therapeutics, Actinium Pharmaceuticals, Inc., Molecular Templates, Inc., NexImmune, Inc., LAVA Therapeutics, Sorrento Therapeutics, Chimerix, Ascentage Pharma Group Inc., Keymed Biosciences, MiNK Therapeutics, and others are evaluating new drugs for refractory multiple myeloma to improve the treatment landscape.
  • Promising refractory multiple myeloma pipeline therapies in various stages of development include NEXI 002, AMG-701, ABBV 453, ALLO-605, PBCAR269A, TAK-981, ABBV-383, ORIC-533, agenT-797, ION251, UCARTCS1A, Y150, Talquetamab, Ipilimumab, LAVA-051, Felzartamab, Elranatamab, RAPA-201, CART-ddBCMA, Magrolimab, PHE885, Marizomib, Teclistamab, HPN-217, CYT-338, ISB 1342, P-BCMA-ALLO1, ALLO-715, ALLO-605, SEA-BCMA, REGN5458, NKTR-255, Iopofosine, EOS-448, CID-103, FT538, MT-0169, NEXI-002, LAVA-051, STI-6129, ONC201, APG-2575, CM336, agenT-797,  and others.
  • In August 2022, Ipsen announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share. Epizyme now operates as ‘an Ipsen company’ at the deal close.

 

Request a sample and discover the recent advances in refractory multiple myeloma treatment drugs @ Refractory Multiple Myeloma Pipeline Report

 

The refractory multiple myeloma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage refractory multiple myeloma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the refractory multiple myeloma clinical trial landscape.

 

Refractory Multiple Myeloma Overview

Multiple myeloma is a type of cancer that begins in a type of white blood cell known as a plasma cell. It’s rare, accounting for less than 2% of all plasma cell tumors, but it’s the most common type, according to the CDC. Although the survival rate of multiple myeloma has improved in recent years, initial refractory multiple myeloma treatment is still ineffective in the vast majority of cases. If myeloma is resistant to treatment or becomes resistant during treatment, it is said to be refractory.

The refractory multiple myeloma symptoms are the same as those of multiple myeloma. These refractory multiple myeloma symptoms either persist or return after treatment. The most common refractory multiple myeloma symptom is bone pain.

 

Learn more about emerging refractory multiple myeloma pipeline therapies @ Refractory Multiple Myeloma Clinical Trials

 

Refractory Multiple Myeloma Therapeutics Assessment

The refractory multiple myeloma pipeline report proffers an integral view of the refractory multiple myeloma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

 

Scope of the Refractory Multiple Myeloma Pipeline Report 

  • Coverage: Global 
  • Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Ophthalmic, Intravenous, Oral, Subcutaneous, Topical, Parenteral, Transdermal
  • Therapeutics Assessment By Molecule Type: Oligonucleotide, Small molecule, Peptide
  • Therapeutics Assessment By Mechanism of Action: Antibody-dependent cell cytotoxicity, Cytotoxic T lymphocyte stimulants, Immunologic cytotoxicity, Small ubiquitin-related modifier protein inhibitors, Natural killer cell replacements, Proto-oncogene protein c-bcl-2 inhibitors
  • Key Refractory Multiple Myeloma Companies: NexImmune, Amgen, AbbVie, Allogene Therapeutics, Precision Biosciences, Takeda Oncology, ORIC Pharmaceuticals, Ionis Pharmaceuticals, Cellectis S.A., YZY Biopharma, Janssen Research & Development, Bristol Myers Squibb, Lava Therapeutics, Prelude Therapeutics, Amgen, Pfizer, Rapa Therapeutics, Arcellx, Inc., Gilead Sciences, Novartis, Celgene Corporation, Genmab, Harpoon Therapeutics, Cytovia Therapeutics, Ichnos Sciences, Poseida Therapeutics, Allogene Therapeutics, Seagen Inc., Regeneron Pharmaceuticals, CFT7455, C4 Therapeutics, CARsgenTherapeutics Co.,Ltd, CELLECTAR BIOSCIENCES, INC., Nektar Therapeutics, iTeos Therapeutics, CASI Pharmaceuticals, Fate Therapeutics, Actinium Pharmaceuticals, Inc., Molecular Templates, Inc., NexImmune, Inc., LAVA Therapeutics, Sorrento Therapeutics, Chimerix, Ascentage Pharma Group Inc., Keymed Biosciences, MiNK Therapeutics, and others.
  • Key Refractory Multiple Myeloma Pipeline Therapies: NEXI 002, AMG-701, ABBV 453, ALLO-605, PBCAR269A, TAK-981, ABBV-383, ORIC-533, agenT-797, ION251, UCARTCS1A, Y150, Talquetamab, Ipilimumab, LAVA-051, Felzartamab, Elranatamab, RAPA-201, CART-ddBCMA, Magrolimab, PHE885, Marizomib, Teclistamab, HPN-217, CYT-338, ISB 1342, P-BCMA-ALLO1, ALLO-715, ALLO-605, SEA-BCMA, REGN5458, NKTR-255, Iopofosine, EOS-448, CID-103, FT538, MT-0169, NEXI-002, LAVA-051, STI-6129, ONC201, APG-2575, CM336, agenT-797,  and others.

 

Dive deep into rich insights for new drugs for refractory multiple myeloma treatment, visit @ Refractory Multiple Myeloma Medications

 

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Refractory Multiple Myeloma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Refractory Multiple Myeloma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Mid Stage Products (Phase I/II)
  9. NEXI 002: NexImmune
  10. Early Stage Products (Phase I)
  11. ABBV 453: AbbVie
  12. Preclinical and Discovery Stage Products
  13. Inactive Products
  14. Refractory Multiple Myeloma Key Companies
  15. Refractory Multiple Myeloma Key Products
  16. Refractory Multiple Myeloma- Unmet Needs
  17. Refractory Multiple Myeloma- Market Drivers and Barriers
  18. Refractory Multiple Myeloma- Future Perspectives and Conclusion
  19. Refractory Multiple Myeloma Analyst Views
  20. Refractory Multiple Myeloma Key Companies
  21. Appendix

 

For further information on the refractory multiple myeloma pipeline therapeutics, reach out @ Refractory Multiple Myeloma Treatment Drugs

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/